Privileged heterocycles for DNA-encoded library design and hit-to-lead optimization
European Journal of Medicinal Chemistry, ISSN: 0223-5234, Vol: 248, Page: 115079
2023
- 13Citations
- 14Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations13
- Citation Indexes13
- 13
- Captures14
- Readers14
- 14
Review Description
It is well known that heterocyclic compounds play a key role in improving drug activity, target selectivity, physicochemical properties as well as reducing toxicity. In this review, we summarized the representative heterocyclic structures involved in hit compounds which were obtained from DNA-encoded library from 2013 to 2021. In some examples, the state of the art in heterocycle-based DEL synthesis and hit-to-lead optimization are highlighted. We hope that more and more novel heterocycle-based DEL toolboxes and in-depth pharmaceutical research on these lead compounds can be developed to accelerate the discovery of new drugs.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0223523422009813; http://dx.doi.org/10.1016/j.ejmech.2022.115079; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85146462132&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/36669370; https://linkinghub.elsevier.com/retrieve/pii/S0223523422009813; https://dx.doi.org/10.1016/j.ejmech.2022.115079
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know